CurveBeam AI Secures A$6.5M Placement at 18% Discount, Adds €10M Vendor Financing

Capital Raise to Fuel Growth

CurveBeam AI Limited (ASX, CVB), a specialist in point-of-care medical imaging technology, has successfully raised A$6.5 million through an institutional placement priced at $0.09 per share, representing a notable discount to recent trading levels. This capital injection is earmarked to bolster sales and marketing efforts for its flagship HiRise™ CT scanner, fund ongoing research and development, and support supply chain and general working capital needs.

The placement attracted both new and existing institutional investors, reinforcing confidence in CurveBeam AI’s growth trajectory. The new shares are expected to be issued in early October, providing the company with fresh liquidity as it targets key milestones in the coming months.

Vendor Financing to Unlock Orthopaedic Market

In a strategic move to overcome capital constraints faced by orthopaedic surgeon offices, CurveBeam AI has secured a €10 million vendor financing facility with a Swiss specialist financier. This arrangement allows surgeons to acquire the HiRise™ device through lease payments spread over four years, effectively lowering upfront costs and broadening market access.

This vendor financing program is expected to accelerate device placements across North America and Europe, positioning CurveBeam AI to capitalize on demand in capital-intensive clinical settings. The facility also covers production and deployment costs, including overheads, providing a comprehensive financial solution aligned with the company’s sales strategy.

Progress on Surgical Robot Validation

CurveBeam AI is advancing validation efforts with a major surgical robotic system vendor to integrate the enhanced HiRise™ scanner. Recent demonstrations and technical discussions have yielded positive feedback, with the company confident that its documentation meets the vendor’s requirements for validation and labelling updates.

While the timeline remains uncertain due to the vendor’s internal processes, successful validation could significantly boost HiRise™ device adoption by enabling seamless integration with robotic surgical workflows.

Strategic Partnership Talks in China

On the international front, CurveBeam AI is negotiating a confidential, non-binding term sheet with a prominent Chinese medical device distributor and manufacturer. The proposed agreement includes a 10-year exclusive distribution and manufacturing license for China, Hong Kong, Macau, and Taiwan, alongside a potential A$10 million equity investment contingent on performance milestones.

This partnership could open a substantial new market for CurveBeam AI’s products, leveraging local manufacturing and distribution capabilities. However, the deal remains subject to final approvals and conditions, with the company aiming to provide further updates in early 2026.

Looking Ahead

CurveBeam AI also anticipates FDA clearance for its bone mineral density SaaS solution within the first half of 2026, complementing its hardware offerings. The company expects to close the first quarter of fiscal 2026 with approximately A$2 million in cash, bolstered by the recent placement proceeds.

With four HiRise™ purchase orders targeted for the quarter, CurveBeam AI is positioning itself for a pivotal phase of commercial expansion supported by innovative financing, strategic partnerships, and regulatory progress.